Researchers have reported a major breakthrough in the treatment of advanced pancreatic cancer, one of the deadliest forms of cancer. A new experimental tablet, called daraxonrasib, has been shown to nearly double the survival time of patients with advanced disease, raising hopes for a long-awaited improvement in treatment options.
The findings were published in the New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Targeting a Key Cancer-Driving Protein
The drug works by blocking a mutated protein that fuels tumor growth in more than 90 percent of pancreatic cancer cases. Scientists have struggled for decades to effectively target this protein, making the latest results particularly significant.
“This is not a cure, but it is a major step forward,” said Dr. Zev Wainberg of the University of California, Los Angeles (UCLA), who led the study.
Trial Shows Significant Survival Benefit
The clinical trial involved 500 patients whose cancer had already spread beyond the pancreas. Participants were divided into two groups: one received the experimental tablet, while the other underwent standard chemotherapy.
According to the study, patients who took daraxonrasib survived an average of 13.2 months, compared with 6.7 months for those receiving chemotherapy. Researchers described the improvement as the first substantial survival advantage over chemotherapy seen in this disease.
Better Quality of Life and Fewer Side Effects
In addition to extending survival, the tablet appeared to improve patients’ quality of life. Researchers reported that tumors shrank in many patients, leading to reduced pain and allowing them to remain on treatment longer than those receiving chemotherapy.
Although the drug’s effectiveness gradually declined over time, researchers believe the survival gap between the two groups could widen as follow-up continues.
Future Research to Explore Earlier Use
Experts are now planning to investigate whether the drug can be used in earlier stages of pancreatic cancer. Researchers will also examine whether shrinking tumors with daraxonrasib could make more patients eligible for potentially curative surgery.
Dr. Brian Wolpin of the Dana-Farber Cancer Institute said future studies will focus on determining how the treatment can be integrated into earlier care strategies.
Common Side Effects Identified
The most frequently reported side effects of the drug included skin rashes and mouth sores. Researchers said these side effects were generally manageable and less burdensome than those associated with conventional chemotherapy.
A Critical Need for Better Treatments
Pancreatic cancer remains one of the most challenging cancers to treat because it is often detected only after it has spread to other organs. Overall, the five-year survival rate for pancreatic cancer patients is approximately 13 percent.
The promising results from the daraxonrasib trial offer renewed optimism that more effective therapies may soon become available for patients facing this aggressive disease.
